Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACP-204 in adults with Lewy body dementia psychosis
2025-521710-25-00Phase 2Authorised
- Sponsor
- Acadia Pharmaceuticals
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial in Lewy body dementia (LBD) comparing ACP-204 with Placebo (2 arms). Primary endpoint: Change from baseline in SAPS-LBDP total score at Week 6. Planned start Dec 2025; status: authorised.
02
Drugs
remlifanserin
03
Conditions
Lewy body dementia (LBD)
Beyond the preview
Go deeper on 2025-521710-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521710-25-00.